NOVN CH0012005267

Report

Real-time Estimate Cboe Europe - 07:36:28 2023-01-31 am EST
82.73	CHF		-0.54%

01/30	Novartis' Sandoz Unit Wins EU Health Agency Panel's Backing for Humira Biosimilar	MT
01/30	Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar	GL
01/30	Novartis : Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar	DJ

Intron Health Lifts Price Target on Novartis, Maintains Buy Recommendation

11/30/2022 | 05:00am EST

All news about NOVARTIS AG

01/30	Novartis' Sandoz Unit Wins EU Health Agency Panel's Backing for Humira Biosimilar	MT
01/30	Sandoz receives positive CHMP opinion for citrate-free high concentration formulation o..	GL
01/30	Novartis : Sandoz receives positive CHMP opinion for citrate-free high concentr..	DJ
01/27	Novartis Says Initial Data from Phase 3 Trial Show No Difference Between Crizanlizumab,..	MT
01/27	Novartis : provides update on Phase III STAND trial assessing crizanlizumab	PU
01/25	Novartis Files Petition With Supreme Court to Protect Gilenya Patent	MT
01/25	NOVARTIS AG : Sell rating from Barclays	MD
01/25	Deciphex Limited announced that it has received €14.8 million in funding from a gr..	CI
01/24	Global markets live: GE, J&J, Verizon, Lockheed Martin, Halliburton...
01/24	Europe's revenue growth expected to slow to a crawl in Q4	RE

Analyst Recommendations on NOVARTIS AG

01/25	NOVARTIS AG : Sell rating from Barclays	MD
01/24	NOVARTIS AG : Goldman Sachs reiterates its Buy rating	MD
01/09	NOVARTIS AG : UBS sticks Neutral	MD

Financials (USD)

Chart NOVARTIS AG

Duration : Period :

Technical analysis trends NOVARTIS AG

	Short Term	Mid-Term	Long Term
Trends	Bearish	Bullish	Neutral

Income Statement Evolution

More Financials

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Sector and Competitors

		1st jan.	Capi. (M$)
	NOVARTIS AG	-0.50%	193 693

NOVARTIS AG